Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | |
|---|---|---|
May 31, 2020 |
May 31, 2019 |
|
| Research and development expenses | $ 1,480,588 | $ 997,861 |
| Stock Options | ||
| Antidilutive securities | 1,590,470 | 1,691,973 |
| Restricted Stock Units | ||
| Antidilutive securities | 4,302,527 | 403,767 |
| Warrants | ||
| Antidilutive securities | 5,084,331 | 962,132 |
| Common Stock | ||
| Antidilutive securities | 0 | 1,000,000 |